Aside these risk factor, consistent with the well documented role of BCL6 in the initiation, therapy evasion, and progression of hematological malignancies, including DLBCL [11,26,27,28,29,30,31,32,33,34,35], it is conceivable that this worse prognosis is associated with the high expression of BCL6 protein in most of these BCL2 DHL cases (62.5% BCL6+ vs. 37.5% BCL6−). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.